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To determine the association between hormonal contraceptive (HC) use, and behaviour-
related and biological cardiovascular risk factors among teenage girls in Germany.  
METHODS  
HC use was assessed among 2285 girls aged 13-17 years who participated in the health 
survey for children and adolescents (German Health Interview and Examination Survey for 
Children and Adolescents, KiGGS), between years 2003 and 2006. Prevalence of HC use 
was determined according to sociodemographic variables, behavior-related health risks, and 
overweight status. We compared HC users and nonusers with respect to biological 
cardiovascular risk factors, including systolic and diastolic blood pressure, and serum 
concentrations of lipids, lipoproteins, high sensitivity C-reactive protein (hs-CRP), and 
homocysteine.   
RESULTS 
HC users were more likely than nonusers to combine several behavior-related health risks, 
independent of sociodemographic factors. In particular, HC use was strongly associated with 
current smoking (odds ratio: 3.4, 95% confidence interval: 2.7-4.3). HC use and behavioral 
factors showed an additive effect on biological cardiovascular risk factors, explaining 
between 6% and 30% of the population variance. Relative contributions of HC use ranged 
from <1% for systolic and diastolic blood pressure to 12% for hs-CRP.   
CONCLUSIONS 
HC use among 13-17-year old girls in Germany is significantly correlated with a more 
unfavorable cardiovascular risk profile, which is partly explained by a clustering of behavioral 
risk factors among HC users. When prescribing HC to teenagers, physicians should 
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systematically assess avoidable behavioral cardiovascular risk factors and provide 
counseling tailored to the risk profile of the individual patient.  
 





Hormonal contraceptives (HCs) have been recommended for the prevention of unintended 
pregnancies among adolescents in Germany because they are considered relatively safe as 
compared with other methods of contraception [1]. In addition, the use of HCs among 
adolescents may have positive effects on certain hormonal disorders such as dysmenorrhea, 
irregular menstrual cycles, and acne [2]. However, HCs have also been associated with 
adverse health effects. In epidemiological studies conducted among adult women, 
cardiovascular health risks, such as venous thrombosis, ischemic and hemorrhagic stroke, 
and myocardial infarction have been shown to be higher among users of HCs than among 
nonusers [3-8]. Consequently, the estrogen content of HCs has been gradually reduced from 
150 µg to 35, and the progestin component has been modified. HCs available on the market 
currently are considered to have fewer adverse health effects because of this lower estrogen 
content and altered progestin; however, some studies with more recently introduced 
preparations do not support this view [9, 10]. 
 
Evidence on health risks of HC use among adolescents is scarce. Events such as venous 
thrombosis, stroke, and myocardial infarction occur rarely in adolescents, thus, hard endpoint 
studies would require extended follow-up far into adulthood. Previous epidemiological studies 
on HCs and cardiovascular risk in adolescents focused on behavioral risk factors relevant to 
cardiovascular risk or surrogate endpoints, such as blood pressure and serum lipids [11-16]. 
These studies were conducted in the 1980s or 1990s, and few studies were population-
based.  
 
We present recent and nationally representative data on the association between current HC 
use, health-related behaviors, and main biological cardiovascular risk factors among teenage 
girls in Germany. We specifically asked: (1) Is there a significant association between HC 
use and behavioral as well as biological cardiovascular risk factors among adolescent girls in 
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Germany? (2) What is the relative contribution of HC use in models of biological risk factors 




Data source and study population 
The German Health Interview and Examination Survey for Children and Adolescents 
(KiGGS) was conducted by the Robert Koch Institute between May 2003 and May 2006. The 
target population of the survey consisted of all noninstitutionalized children and adolescents 
aged 0-17 years living in Germany. The design, sampling strategy, and study protocol have 
been described elsewhere in detail [17]. Briefly, a two-stage random clustered sample of the 
target population was drawn on the basis of a representative sample of German communities 
[17].  The study was conducted according to a highly standardized protocol encompassing a 
medical computer-assisted interview, self-administered questionnaires, and standardized 
physical examinations including blood pressure measurements and casual venous blood 
sampling for biochemical tests. The final sample included 17,641 children and adolescents 
(8,985 boys, 8,656 girls). The overall response rate was 66.6% (69% in age group 11-13 
years; 63% in age group 14-17 years). Nonresponse analysis showed little variation between 
the age groups and sexes, and no difference was found with respect to health-related 
variables [17]. The survey was approved by federal data protection officials and by the 
Charité Universitätsmedizin Berlin medical ethics committee. Written informed consent was 
obtained before the interview and examination from the children’s parents and the children 
themselves if they were over 14 years of age. This study was restricted to the 2,307 girls 
aged 13-17 years who participated in the KiGGS. Of them, 22 girls who did not take part in 
the drug use survey were excluded, resulting in a study population of 2,285 girls available for 
the present analysis. 
 
Assessment of hormonal contraceptive use 
Survey participants were asked in advance to bring prescriptions or original medicine 
containers to the examination sites. Use of any medication, including prescription drugs and 
over-the-counter medications, within seven days before the medical examination was 
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assessed using a computer-assisted standardized drug use questionnaire. Details of 
medication use were documented, such as brand name, condition(s) treated, daily dosage, 
route of application, and duration of use. Specific ATC (Anatomical Therapeutic Chemical) 
codes were assigned to all reported medications and WHO ICD-10 codes to the conditions 
for which the medications were taken. For each medication recorded,  a maximum of two 
conditions could be provided. We identified a total of 445 participants who took medications 
with ATC-codes G03A (HCs for systemic use, n=428), G03HB01 (combinations of 
cyproterone acetate (antiandrogen) and estrogens, for treatment of acne and hirsutism, 
n=15), and G02B (contraceptives for topical use, n=2).  
 
Definition of behavioral cardiovascular risk factors, biological cardiovascular risk factors, and 
sociodemographic covariates  
Behavioral cardiovascular risk factors included cigarette smoking, regular alcohol 
consumption, physical activity assessed as engagement in sports activities, and overweight 
status measured as body mass index (BMI) class. Standardized, self-administered 
questionnaires were used to collect information regarding behavior-related health risks and 
sociodemographic characteristics. Questionnaires were tailored to specific age groups (e. g., 
11-13 years; 14-17 years) to capture health-related information of particular relevance to 
important developmental stages. Separate questionnaires were offered to the parents and to 
the children aged 11 years [17]. We used information provided by the girls themselves to 
define health-related behavior. Girls were classified as current smokers if they answered the 
question “Do you currently smoke?” with “daily”, “several times a week”, “once a week”, or 
“occasionally”. Regular alcohol consumption was defined as drinking a minimum of one glass 
of beer, wine, or hard liquor per week. The frequency of physical activity was assessed with 
the question, “In your leisure time, how often do you engage in physical activity (e.g., when 
doing sports or riding bicycle) that leads to heavy sweating or being out of breath?” with the 
answer choices “about every day”, “three to five times a week”, “about once or twice a week”, 
“about once or twice a month”, or “never”. For the present analysis, the frequency of physical 
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activity was defined as “often” (three to five times a week or more), “sometimes” (about once 
or twice a week, or about once or twice a month), and “never”. BMI was computed from 
standardized measures of children’s weight and height. Relative body weight was classified 
as normal, overweight, or underweight according to Kromeyer-Hauschild (overweight: BMI 
above the age- and sex-specific 90th percentile; underweight: BMI below the age- and sex-
specific 10th percentile) [18]. In some regression models, we included pubertal stage as self-
reported Tanner stage of pubic hair (stage 1: Tanner 1; stage 2: Tanner 2-3; stage 3: Tanner 
4-6) and menarche status (yes/no) as additional factors [19]. 
 
Biological cardiovascular risk factors included blood pressure and serum concentrations of 
total cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein 
cholesterol (HDL-C), triglycerides, high sensitivity C-reactive protein (hs-CRP), and 
homocysteine. Analytical methods have been previously described in detail [20]. 
Standardized measurements of systolic, diastolic, and mean arterial pressure were obtained 
using an automated oscillometric blood pressure device. The means of two independent 
readings for systolic blood pressure (SBP) and diastolic blood pressure (DBP) were used in 
the present analysis.  
 
Because associations between HC use and certain sociodemographic factors, such as 
residence in East or West Germany, family social status, and family immigration background, 
were conceivable, these covariates were included in regression models. The 10 federal 
states of the Federal Republic of Germany before reunification were defined as West 
Germany, the five new federal states covering the region of the former German Democratic 
Republic and the federal state of Berlin were defined as East Germany. Family social status 
score was computed integrating information obtained from the parents’ questionnaire on both 
parents’ educational level and professional status as well as total family income [17, 21]. 
Family immigration status was assessed on the basis of the information collected on 
nationality, country of birth, and year of immigration of both parents [17]. Girls were classified 
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as having an immigration background if either they themselves had immigrated from another 
country and at least one parent was not born in Germany, or if both parents were immigrants 
or not of German nationality.  
 
Statistical analysis 
Multivariable logistic regression was applied to identify independent determinants of HC use; 
results are expressed as adjusted odds ratios and 95% confidence intervals. Analysis of 
covariance was applied to compare mean levels of biological cardiovascular risk factors 
between HC users and nonusers, accounting for the effect of modifiable behavioral 
cardiovascular risk factors (smoking, alcohol consumption, physical activity), overweight 
status, pubertal stage, and sociodemographic covariates. As serum CRP and triglyceride 
measures showed a highly skewed distribution, values were logarithmically transformed for 
statistical analyses. Comparisons of adjusted means were extended to subgroups of HC 
users defined by duration of HC use ( 1 year vs. <1 year), estrogen dose (<20, 20-30, >30 
g), and progestin component (levonorgestre l= second generation; desogestrel and 
norgestimat = third generation; drospirenone and dienogest = fourth generation). Multiple 
linear regression models were fitted to assess the relative contribution of HC use in 
explaining the population variance of biological cardiovascular risk factors as dependent 
variables. A total of 130 (5.7%) study participants had missing observations in one or more 
variables. Missing values were excluded in multivariable regression modeling. All statistical 
analyses were performed using SPSS statistical software (release 17.0; SPSS Inc., Chicago, 
IL). A probability level of p <0.05 based on two-sided tests or 95% confidence intervals that 
did not overlap was considered statistically significant. To ensure that survey results are 
representative at the population level, all results were weighted by a survey weighting factor, 
considering deviations between survey responders and the actual German population 
structure (as of December 31, 2004) with respect to demographic characteristics (age, sex, 
residence in West or East Germany, nationality) [17]. The complex sample method was used 




Overall prevalence, indications, and patterns of current hormonal contraceptive use  
Overall, 19.6% among girls aged 13-17 years were currently using HCs (Table 1). About 
98% of HC users reported oral contraceptive preparations. Nonoral application routes 
included transdermal patches, hormonal implants, or injections. Overall, 11% of HC users 
took HC preparations exclusively for the treatment of medical disorders, mainly 
dysmenorrhoea, irregular menstrual cycles, or acne (data not shown). Nearly one-half 
(49.1%) of HC users reportedly had been using HCs for a minimum of 1 year (data not 
shown). The most frequently used oral HCs (91.5%) were single-phase combined 
preparations with a fixed amount of ethinyl estradiol and progestin. About two-thirds of users 
of oral HCs used preparations that contained 30 µg of ethinyl estradiol, 12% used HCs with 
more than 30 µg ethinyl estradiol, and 23% used HCs with 20 µg ethinyl estradiol (data not 
shown). About 35% of combined oral contraceptives that were used by the study participants 
contained levonorgestrel as progestin component. Combined oral contraceptives with 
desogestrel, chlormadinone acetate, or dienogest were used by approximately 16% of HC 
users each (data not shown).  
 
Sociodemographic determinants of current hormonal contraceptive use 
The prevalence of HC use increased continuously with age, ranging from 0.2% among 13-
year-olds to 45.6% among 17-year-olds (Table 1). HC use was significantly and inversely 
related to residence in West versus East Germany and to immigration background (Table 1). 
No significant association was found between HC use and family social status (Table 1). 
Results persisted in multivariable logistic regression of HC use on sociodemographic factors 
(data not shown). Considering individual components of social status, for example, parental 
education levels or household income, in separate models also did not change the results 
(data not shown). 
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Association between hormonal contraceptive use and modifiable health-related behavioral 
risk factors  
As compared with nonusers, HC users were significantly more likely to be current smokers 
(56% vs. 20%), to consume alcohol on a regular basis (38% vs. 14%), and to report not to be 
involved in any sports activity (24% vs. 15%) (Table 1). Age-stratified analysis showed that 
group differences between HC users and nonusers declined with increasing age (Figure 1). 
Among girls aged <16 years, current HC use was significantly related to all three behavior-
related cardiovascular risk factors. Significant differences between HC users and nonusers 
were reduced to current smoking and alcohol use among 16-year-old girls and to current 
smoking alone among 17-year-old girls (Figure 1). Consistently, HC users and nonusers did 
not significantly differ with respect to overweight status (Figure 1). HC users were more likely 
than nonusers to have combinations of behavioral cardiovascular risk factors (cigarette 
smoking, alcohol consumption, inactivity, and being overweight). Overall, 80% of HC users 
had at least one out of the four selected risk factors as opposed to 47% of nonusers. A total 
of 25.2% of HC users had two, and 14.5% had three or four of the risk factors considered, in 
contrast to 13.5% and 3.1%, respectively, among non-users (data not shown in Figure 1). 
Associations between individual behavioral cardiovascular risk factors and HC use were 
reduced but not fully explained in multivariable logistic regression analyses, adjusting for 
sociodemographic variables (Table 2). Results did not materially change when 13- and 14-
year-old girls were excluded from the regression model (e.g., OR for smoking was then 3.10 
(2.45-3.93)).  
 
Independent associations between current HC use and biological cardiovascular risk factors 
Adjusting for behavioral cardiovascular risk factors, sociodemographic covariates, and 
pubertal stage, HC users had significantly higher mean SBP and DBP, and higher mean 
serum concentrations of total cholesterol, HDL-C, LDL-C, triglycerides, and hs-CRP as 
compared with nonusers (Table 3). No statistically significant association was observed 
between HC use and serum homocysteine. Absolute differences between HC users and 
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nonusers increased with extended duration of HC use (≥ 1 year vs. < 1 year), although group 
mean differences between short term (<1 year) and longer term (≥ 1 year) users did not 
reach statistical significance (p values not shown in Table 3). Mean levels of biological 
cardiovascular risk factors did not consistently differ in relation to estrogen content or 
progestin generation with the exception of mean serum HDL-C concentrations. These were 
significantly higher among HC users of preparations with higher estrogen content (30 or >30 
g vs. 20 g) as well as among users of preparations containing third- and fourth-generation 
progestins compared with users of preparations containing second-generation progestins 
(data not shown).  
 
In general linear models including sociodemographic variables, behavioral cardiovascular 
risk factors, and pubertal stage, HC use explained a small to moderate additional proportion 
of the population variance of biological cardiovascular risk factors (Table 4). Relative 
contributions of HC use ranged between <1% in models with SBP or DBP as dependent 
variables and 12.3% in models with hs-CRP as the dependent variable (Table 4). We 
observed no interaction between HC use and smoking or other behavioral cardiovascular risk 




Overall, 19.6% of 13-17-year-old girls in Germany were currently using HCs. This prevalence 
estimate is consistent with results obtained from a previous interview survey conducted 
among 14-17-year-old girls in Germany, despite methodological differences in study design 
[22]. Our results are also similar to prevalence estimates reported by other western 
European countries [11, 23, 24].  
 
In contrast to a previous study among Finnish teenagers [25] but in agreement with study 
results obtained among adult women in Germany [26], we did not find an association of HC 
use with family social status or individual components of this construct, that is, educational or 
professional status or household income. As observed in the present study, differences in 
social status and educational background might in part be captured by regional and cultural 
differences in HC use. As expected, HC use among teenage girls was strongly and inversely 
correlated with a family immigration background. Most of the families immigrating to 
Germany have an Islamic background, thus, cultural and religious influences are likely to 
restrict the proportion of sexually active girls and the demand for HCs. As observed among 
teenagers in the present study, HC use among adult women was previously reported to be 
significantly higher in eastern German federal states than in western federal states [26, 27], 
possibly because of easier access to this contraceptive method in the former German 
Democratic Republic [27]. Although differences in health and health-related behavior 
between children and adolescents living in former East and West Germany have almost 
disappeared within the 20 years since reunification [28], the mother’s preference may 
conceivably affect the daughter’s choice of contraception method.  
 
An association between HC use and unhealthy lifestyle, in particular current cigarette 
smoking, was found in our study as well as in others [11-14, 29]. Clustering of behavioral 
cardiovascular risk factors among adolescents has been previously observed to be 
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associated with an adverse biological cardiovascular risk profile [13]. Previous studies 
conducted among adolescents reported an association of HC use and elevated SBP, DBP,  
serum total cholesterol and LDL-C [11, 13-16]. Studies that were conducted in the 1970s and 
1980s found decreased HDL–C levels among HC users as compared with nonusers [16, 30]. 
In contrast, in the present study, HDL–C levels were higher among HC users than nonusers, 
most likely because of the differences in the progestin component between older and more 
recently developed oral contraceptives. Elevated levels of serum hs-CRP in association with 
HC use have been previously described in studies of adolescent girls [31] as well as adult 
women [32-34]. In agreement with other studies, we did not find evidence for an association 
between HC use and homocysteine levels [31].  
 
In addition to previous investigations, the present study assessed the joint effect of HC use 
and main modifiable behavior-related health risks as well as the relative contribution of HC 
use on biological cardiovascular risk factors.  We observed an additive effect of HC use and 
behavioral health risk factors. In particular, we found no interaction between HC use and 
smoking, although a synergistic effect of smoking and HC use on cardiovascular risk has 
been described by some studies [35, 36]. Relative contributions of HC use on biological 
cardiovascular risk factors were small (<1 -12%).  
 
The clinical relevance of the association between HC use and established cardiovascular risk 
factors among adolescent HC users remains unclear. The risk of cardiovascular events, in 
particular stroke, or venous thromboembolism is considered low among adolescent HC 
users, unless a genetic predisposition for thrombosis exists [2, 37]. As risk considerably 
increases with age, heavy smoking is a contraindication of HC use for adult women, 
especially for those aged >35 years according to guidelines of the German Society of 
Gynaecology and Obstetrics. A small increase in SBP or DBP is probably not clinically 
relevant for healthy adolescent girls, but may be relevant for girls with established 
hypertension. Elevated levels of total serum cholesterol, LDL-C, and triglycerides are 
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associated with an increased cardiovascular disease risk, whereas elevated levels of HDL–C 
associated with HC use are considered beneficial with respect to cardiovascular disease risk. 
Elevated levels of serum hs-CRP, if not caused by an acute infection, have been associated 
with cardiovascular disease risk, in particular risk of atherosclerotic degenerative processes 
[38]. However, it is subject to debate whether hs-CRP is an indicator or an inducer of 
atherosclerotic processes [39]. To determine the clinical relevance of the observed 
associations of HC use and biological cardiovascular risk factors, tracking of risk factors and 
the development of subclinical disease in association with HC use need to be investigated 
prospectively in population-based cohorts of adolescent girls.  
 
The main strength of the present study is that HC use could be investigated in a nationally 
representative sample of 13 - 17-year-old girls in Germany. Recall bias with respect to 
medication use was minimized because questions referred to the 7 days before the interview 
rather than a longer period. In addition, study participants were encouraged to bring their 
prescriptions or medication packages to the medical interview, which increased the quality of 
medication use data. There are limitations to our study. Because of the cross-sectional study 
design, neither the clinical relevance nor the causality of the observed association between 
HC use and biological cardiovascular risk factors can be established. Also, we cannot 
exclude misclassification bias caused by underreporting. Although some study participants 
may have chosen not to admit to HC use during the interview, the number is likely to be 
small. Ethnicity of the study participants could be a confounding factor because biological 
cardiovascular risk factors are well known to differ by ethnicity. The present study included a 
representative proportion of adolescents with immigration background. However, this group 
was largely dominated by study participants with a Turkish background, whereas the number 
of black or Asian children was very small. Thus, the present study did not permit to 
differentiate between ethnically distinct subgroups.  
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Among healthy girls, small increments in cardiovascular risk are likely to be outweighed by 
the benefits of HC use, mainly protection from teenage pregnancy. However, the strong 
correlation between HC use and avoidable risk behaviors, in particular cigarette smoking, is 
of public health concern. Because HCs are only available on prescription, physicians 
prescribing them should take the opportunity to systematically assess the occurrence of 
modifiable behavior-related risk factors and provide evidence-based counseling tailored to 
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Legend to Figure 1 
 
Figure 1: Distribution of behavioral cardiovascular risk factors according to current hormonal 
contraceptive use among 13- to 17-year-old girls in Germany. German Health Interview and 
Examination Survey for Children and Adolescents (KiGGS), 2003-2006. * p<.05, ** p<.001, 





Table 1. Characteristics of the study population and prevalence of current hormonal 
contraceptive (HC) use among 13- to 17-year old girls in Germany. German Health 







 Prevalence of HC 
use  
  N (%) N (%) N (%)  % (95% CI) 
Total  2,285 (100) 1,840 (100) 445 (100)  19.6 (17.9-21.4) 
Age group*, years       
13 467 (18.6) 465 (23.1) 2 (0.2)  0.2 (0.0-0.7) 
14 462 (20.4) 443 (24.5) 19 (3.3)  3.1 (1.9-5.1) 
15 462 (20.2) 389 (21.3) 73 (15.5)  15.0 (11.7-19.0) 
16 448 (20.5) 302 (17.4) 146 (33.6)  32.0 (27.8-36.6) 
17 446 (20.4) 241 (13.8) 205 (47.5)  45.6 (40.6-50.6) 
Region*      
East Germany 779 (20.3) 590 (18.5) 189 (28.0)  27.0 (23.4-30.9) 
West Germany 1,506 (79.7) 1,250 (81.5) 256 (72.0)  17.7 (15.9-19.6) 
Family immigration 
background*  
   
 
Yes 329 (16.8) 303 (19.3) 26 (6.5)  7.6 (5.1-11.2) 
No 1,953 (83.1) 1,534 (80.6) 419 (93.5)  22.0 (20.1-24.0) 
Missing 3 (0.1) 3 (0.1) 0   
Family social status      
Lower 584 (26.0) 473 (26.2) 111 (25.3)  19.0 (15.9-22.6) 
Intermediate 1,067 (46.0) 847 (45.3) 220 (48.8)  20.7 (18.2-23.6) 
Upper 563 (24.9) 458 (25.1) 105 (24.2)  19.0 (15.9-22.7) 
Missing 71 (3.1) 62 (3.4) 9 (1.6)  10.5 (5.2-20.0) 
Body mass index      
Underweight 152 (6.4) 128 (6.8) 24 (4.7)  14.5 (9.4-21.7) 
Normal 1,728 (75.9) 1,383 (75.6) 345 (77.4)  19.9 (18.0-22.0) 
Overweight 390 (17.0) 316 (16.9) 74 (17.4)  20.1 (16.1-24.7) 
Missing 15 (0.7) 13 (0.8) 2 (0.4)  11.3 (2.7-37.0) 
Physical activity*      
Often 880 (38.4) 750 (40.5) 130 (29.8)  15.2 (12.8-17.9) 
Sometimes 996 (43.9) 791 (43.5) 205 (45.6)  20.3 (17.8-23.0) 
Never 376 (16.4) 271 (14.6) 105 (23.6)  28.2 (23.5-33.5) 







Yes 620 (27.0) 376 (20.1) 244 (55.7)  40.3 (36.3-44.4) 
No 1,646 (72.2) 1,450 (79.2) 196 (43.5)  11.8 (10.2-13.6) 







Yes 409 (18.7) 250 (14.1) 159 (37.8)  39.5 (34.4-44.8) 
No 1,837 (79.5) 1,555 (83.9) 282 (61.4)  15.1 (13.4-17.0) 
Missing 39 (1.8) 35 (2.0) 4 (0.8)  8.7 (2.9-23.6) 
Pubertal stage      
Stage 1 (Tanner 1) 4 (0.2) 4 (0.2) 0   
Stage 2 (Tanner 2-3) 121 (4.8) 112 (5.5) 9 (1.8)  7.3 (3.4-16.0) 
 23
Stage 3 (Tanner 4-6) 2,119 (93.6) 1,691 (92.8) 428 (96.9)  20.2 (18.5-22.1) 
Missing 41 (1.5) 33 (1.5) 8 (1.4)  18.0 (7.7-36.5) 
Menarche       
Yes 2,086 (91.8) 1,642 (89.9) 444 (99.9)  21.3 (19.4-23.2) 
No 184 (7.6) 184 (9.4) 0  0 
Missing 15 (0.6) 14 (0.7) 1 (0.1)  3.9 (0.5-24.1) 
Percentages and prevalence data were weighted according to the national child population in 
Germany.  
 







Table 2: Odds ratios (OR) and 95% confidence intervals (CI) of HC use according to 
behavioral cardiovascular risk factors among 13- to 17-year old girls in Germany. 







BMI   
Normal weight 1  
Underweight  0.68 (0.44-1.05) 0.64 (0.39-1.05) 
Overweight  0.98 (0.76-1.27) 0.88 (0.66-1.19) 
Physical activity   
Often 1  
Sometimes 1.43 (1.15-1.78) 1.21 (0.94-1.55) 




No 1  




No 1  
Yes  3.67 (2.96-4.54) 1.62 (1.27-2.07) 
a Results obtained from multivariable logistic regression models adjusted for age, region 








Table 3: Adjusted mean levels of biological cardiovascular risk factors according to 
hormonal contraceptive use among 13- to 17-year-old girls in Germany. German 
Health Interview and Examination Survey for Children and Adolescents (KiGGS), 2003-
2006   
Hormonal contraceptive users 
Duration of use Risk factor  
Non-users 
(N=1840) Total users 
(N=445) <1 year (n=173) >=1 year (n=167) 
SBP,  mm Hg 113.60.33 115.20.66* 113.50.96 115.90.83* 
DBP,  mm Hg 68.60.23 69.90.42** 69.10.67 70.20.61* 
     
Total-C, mg/dl 161.60.92 184.42.50*** 179.92.99*** 190.75.07*** 
HDL-C, mg/dl 57.90.37 61.71.00*** 60.31.18 63.61.67** 
LDL-C, mg/dl 91.30.82 108.92.5*** 106.23.01*** 113.74.70*** 
Triglycerides, 
mg/dl 
87.41.02 113.31.03*** 111.41.03*** 117.31.04*** 
     
hs-CRP, µg/dl 43.31.03 123.11.07*** 113.81.11*** 140.91.10*** 
     
Homocysteine, 
µmol/l 
7.970.07 7.690.14 7.580.25 7.850.23 
Data are presented as mean  SEM. 
Values for triglycerides and hs-CRP are anti-logs from means of log-transformed values.   
Results obtained from general linear models adjusted for age, region (East/West Germany), 
family immigration background, family social status, as well as overweight status, pubertal 
stage, physical activity, smoking, and alcohol consumption. 
SBP = systolic blood pressure; DBP = diastolic blood pressure; total-C = total serum 
cholesterol; LDL-C = low density lipoprotein cholesterol; HDL-C = high density lipoprotein 
cholesterol; hs-CRP = high-sensitivity C-reactive protein.  










Table 4: Relative contribution of HC use to explain the population variance in 
biological cardiovascular risk factors among 13- to 17-year old girls in Germany. 





 r2 B 95% CI p- value η2 
SBP Model 1 .056    - 
 Model 2 .057 1.29 .28-2.30 .013 .002 
DBP Model 1 .055     
 Model 2 .058 1.18 .41-1.95 .003 .004 
Total-C Model 1 .063     
 Model 2 .124 22.76 19.28-26.25 <.001 .065 
LDL-C Model 1 .052     
 Model 2 .095 17.11 13.95-20.26 <.001 .046 
HDL-C Model 1 .054     
 Model 2 .066 4.20 2.72-5.67 <.001 .013 
Triglycerides Model 1 .065     
 Model 2 .098 1.29 1.23-1.37 <.001 .034 
CRP Model 1 .197     
 Model 2 .295 2.97 2.64-3.35 <.001 .123 
 
Results obtained from general linear models.  
Model 1: adjusted for age, region (East/West Germany), family immigration background, 
family social status, pubertal stage, overweight status, physical activity, current cigarette 
smoking, and alcohol consumption 
Model: 2: Model 1+HC use 
SBP = systolic blood pressure; DBP = diastolic blood pressure; total-C = total serum 
cholesterol; LDL-C = low density lipoprotein cholesterol; HDL-C = high density lipoprotein 
cholesterol; hs-CRP = high-sensitivity C-reactive protein.  
 
 
 
 
